Septerna
- 18/07/2023
- Series B
- $150,000,000
Septerna is on a mission to make the promise of future GPCR medicines a reality for patients. Combining the latest advances in biochemical, structural and computational drug discovery approaches, we have built an industrialized platform to precisely control and modulate GPCR biology and pharmacology to discover and develop new high-impact medicines. With our Native Complex™ platform, we are opening a new frontier in GPCR small molecule discovery technologies to expand the druggable GPCR landscape.
We are always looking for talented scientists, drug hunters, and business professionals to join our mission to launch a new era of GPCR medicines. If you’re passionate about innovation, energized by teamwork, and fueled by the desire to change patient lives, join us and become a part of the Septerna story!
- Industry Biotechnology
- Website https://septerna.com/
- LinkedIn https://www.linkedin.com/company/septernainc/